- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01765400
Platelet Inhibition in Patients With Systolic Heart Failure
Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Thienopyridine antiplatelet agents are an important component of therapy for management of acute coronary syndrome (ACS). Dual antiplatelet therapy with a thienopyridine, most commonly clopidogrel, and aspirin is widely used in the management of ACS to prevent major adverse cardiovascular events. Despite the benefits of this regimen, many patients continue to develop atherothrombotic events while on this regimen. Various reasons including inter-patient variability, delayed onset of action, and the obtainable antiplatelet activity of clopidogrel have been described as potential causes of the limited efficacy in preventing recurrent events. The Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction (TRITON-TIMI 38) showed that patients with moderate-to-high-risk ACS scheduled for percutaneous coronary intervention (PCI) treated with prasugrel had decreased cardiovascular events compared to clopidogrel.
Clopidogrel is a prodrug that requires two hepatic conversion steps by the cytochrome (CYP)P450 enzyme system. The need for CYP450 involvement is known to contribute to the variable response of platelet inhibition demonstrated with clopidogrel. Although prasugrel is also a thienopyridine, it only requires hepatic CYP450 enzymes for one conversion step, and is converted to the active metabolite more efficiently. Therefore, prasugrel provides significantly more potent platelet inhibition compared to clopidogrel.
Patients with advanced systolic heart failure commonly have elevated hepatic venous pressures that can cause hepatic congestion and hypoperfusion resulting in impaired hepatic function. The elevated hepatic venous pressure predominantly affects the hepatic centrilobular cells which contain the highest concentration of cytochrome P-450 (CYP450) enzyme system. Hence patients with advanced heart failure may convert less clopidogrel to the active metabolite and subsequently produce less platelet inhibition compared to prasugrel.
Since prasugrel only requires the CYP450 system for one conversion step, the impact of hepatic congestion should be limited for heart failure patients treated with prasugrel. The phase 3, multi-center TRITON-TIMI 38 trial comparing clopidogrel and prasugrel showed that in an unselected patient population presenting with ACS, prasugrel achieved greater cardiovascular event reduction that was attributed to more robust platelet inhibition. Hence, we designed this trial to prospectively test the hypothesis that systolic heart failure patients with increased circulating catecholamines and possible abnormal functioning of CYP450 system treated with prasugrel will achieve greater platelet reactivity inhibition compared to those treated with clopidogrel.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebaska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients 19 to 74 years of age.
- Patients with a left ventricular ejection fraction <35% by echocardiogram, SPECT myocardial perfusion study, cardiac MRI, cardiac computerized tomographic angiogram or invasive left ventricular angiogram within the last 6 months.
- Patients with NYHA Class III-IV heart failure at the time of enrollment.
Exclusion Criteria:
- Recent hospitalization within 30 days
- Patients expected to undergo major surgery or PCI in the next 30 days
- Patients taking clopidogrel, prasugrel, ticagrelor, ticlopidine, or cilostazol
- Patients listed for heart transplantation or having left ventricular assist device placement
- Patients with known allergy to either medication
- Patients with prior history of stroke or transient ischemic attack
- Patients with known intracranial neoplasm, aneurysm, or arteriovenous malformation
- Patients with a history of bleeding requiring hospitalization for treatment
- Patients taking oral anticoagulants
- Patients with body weight <60 kg
- Women who are pregnant or breastfeeding
- Patients with hemoglobin <10 mg/dl or platelet count <100,000/ul at baseline
- Patients with known clotting or platelet disorders
- Patients with a baseline INR > 1.4
- Patients with liver function tests (AST or ALT) > 2 times normal
- Patients with a suspected change in their use of aspirin during the study (starting, stopping, or changing dose of aspirin)
- Patients unwilling to consent to CYP2C19 genetic testing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prasugrel
Prasugrel oral 10 mg once daily for 2 weeks
|
|
Active Comparator: Clopidogrel
Clopidogrel oral 75 mg once daily for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication
Time Frame: Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel, Change From Baseline at Week 2 Reported
|
Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel, Change From Baseline at Week 2 Reported
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Change in Light Transmission Aggregometry (LTA)Between Baseline and Each Antiplatelet Medication
Time Frame: Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel
|
Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel
|
The Change in Platelet Activation Assay (VASP)Between Baseline and Each Antiplatelet Medication
Time Frame: Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel
|
Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul P Dobesh, PharmD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Murmurs
- Heart Failure
- Systolic Murmurs
- Heart Failure, Systolic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Clopidogrel
- Prasugrel Hydrochloride
Other Study ID Numbers
- 0574-11-FB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systolic Heart Failure
-
Central Hospital, Nancy, FranceUnknown
-
Zensun Sci. & Tech. Co., Ltd.Active, not recruitingChronic Systolic Heart FailureChina
-
Zensun Sci. & Tech. Co., Ltd.TerminatedChronic Systolic Heart FailureChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Systolic Heart FailureChina
-
Hospital Moinhos de VentoTakedaUnknownHeart Failure, Systolic | Systolic Heart Failure | Cardiac FailureBrazil
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
Abbott Medical DevicesCompletedSystolic Heart FailureAustralia, Hong Kong, Japan
-
University of CincinnatiCompletedSystolic Heart FailureUnited States
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveKorea, Republic of
-
Novartis PharmaceuticalsCompletedHeart FailureRussian Federation, Germany, Poland
Clinical Trials on Prasugrel 10 mg daily x 2 weeks
-
Oslo University HospitalTakeda Nycomed; Sykehuset Asker og BaerumCompleted
-
Texas A&M UniversityUnknownCancer Patients Receiving Chemotherapy or ChemoradiotherapyUnited States
-
Natrogen Therapeutics International, IncUnknownUlcerative ColitisUnited States
-
University Hospital Inselspital, BerneBaxter Healthcare CorporationCompletedHemodialysis | AnuriaSwitzerland
-
University of OxfordCompleted
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Azienda Ospedaliera Universitaria Integrata VeronaUniversity of MilanUnknown
-
Onorach Clinical LtdCompleted
-
Evandro Chagas Institute of Clinical ResearchNot yet recruitingChronic Chagas DiseaseBrazil